Skip Navigation

Gestational Trophoblastic Disease (GTD) Overview

  • Since 1965, the New England Trophoblastic Disease Center at Dana-Farber/Brigham and Women's Cancer Center, affiliated with the Susan F. Smith Center for Women's Cancers, has treated dozens of patients with gestational trophoblastic disease (GTD). Our physicians and researchers have been the source of more than 300 original research reports and publications, which continue to help improve prevention, early detection, and treatment of this disease.

    The Center's long history of research and treatment has culminated in the largest gestational trophoblastic cancer registry in the United States, providing new insight into the long-term health and psychosocial effects of treatment, including fertility.

    Exceptional Care for Patients with Gestational Trophoblastic Disease (GTD) – You Have...

    • A team of gynecologic oncology specialists who diagnose and treat dozens of patients with gestational trophoblastic disease each year, and are setting treatment guidelines for other physicians around the world
    • Gynecologic medical oncologists who are constantly evaluating novel, targeted therapies through clinical trials, some of which may not be available elsewhere
    • Our gynecologic pathologists, among the largest group of its kind, who have made many significant discoveries regarding the early development of gynecologic cancers, and in particular the diagnosis of GTD
    • Specialized care for women with sexual health or fertility concerns, and access to a wide array of support services and survivorship care